In response to last October’s FDA Patient-Focused Drug Development Guidance public workshop, we concluded our invited comment by raising the concern that the pharmaceutical clinical trial community would be limited to innovate unless we embrace high quality mixed methods patient centered outcomes research. We are, therefore, delighted to read that the FDA is creating a 51-person Office of Drug Evaluation Science, which will include a group focused on clinical outcome assessments. We fully support the effort for innovation and look forward to interacting with agency this year to further improve the accuracy and interpretability of patient centered outcome measurement.